VDR and Parkinson disease: Since 1,25(OH)2D3 treatment significantly recovered P-gp expression at the BBB in the 6-OHDA PD mouse model and in vitro HUVEC model treated with PFF, VDR activation may be considered a therapeutic target to recover P-gp expression and, thus, vascular function in PD.